Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...
Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...
H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...
The overall goal of the Hub is to take world-leading research to commercialisation outcomes such as spinouts and licenses. Along with Trinity, University College Dublin (UCD) and RCSI University of ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...
The overall goal of the Hub is to take world-leading research to commercialisation outcomes such as spinouts and licenses.
EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.
Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback